Paratek Pharmaceuticals Inc (PRTK) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Paratek Pharmaceuticals Inc (Paratek) develops and commercializes therapies based on tetracycline chemistry. Nuzyra (Omadacycline), the company’s lead product candidate is an USFDA approved broad spectrum antibiotic for the treatment of adults with community acquired bacterial pneumonia, acute bacterial skin and skin structure infections caused by susceptible bacteria. Its other product Seysara (sarecycline) is also an USFDA approved drug for the treatment of inflammatory acne vulgaris in patients with aged nine or older. Omadacycline is also being evaluated for the treatment of female patients with uncomplicated urinary tract infection and acute pyelonephritis. Paratek is headquartered in Boston, Massachusetts, the US.

Paratek Pharmaceuticals Inc Key Recent Developments

Nov 05,2020: Paratek Pharmaceuticals announces third quarter 2020 total revenue of $13.7 million
Aug 10,2020: Paratek Pharmaceuticals announces second quarter 2020 total revenue of $9.3 million including NUZYRA (omadacycline) net revenue of $8.1 Million
May 11,2020: Paratek Pharmaceuticals announces first quarter 2020 total revenues of $7.9 million including NUZYRA (omadacycline) net sales of $7.3 million
May 11,2020: Paratek Pharmaceuticals announces first quarter 2020 total revenues of $7.9 million including NUZYRA (omadacycline) net sales of $7.3 million
Nov 12,2019: Paratek Pharmaceuticals generates net revenues of $3.9 million in the third quarter of 2019

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company